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The pre–T cell receptor (TCR) is expressed early during T cell development and imposes a tight 
selection for differentiating T cell progenitors. Pre-TCR–expressing cells are selected to 
survive and differentiate further, whereas pre-TCR
 
  
 
cells are “negatively” selected to die. The 
mechanisms of pre-TCR–mediated survival are poorly understood. Here, we describe the 
induction of the antiapoptotic gene 
 
BCL2A1
 
 (A1) as a potential mechanism regulating 
inhibition of pre–T cell death. We characterize in detail the signaling pathway involved in A1 
induction and show that A1 expression can induce pre–T cell survival by inhibiting activation 
of caspase-3. Moreover, we show that in vitro “knockdown” of A1 expression can compromise 
survival even in the presence of a functional pre-TCR. Finally, we suggest that pre-TCR–
induced A1 overexpression can contribute to T cell leukemia in both mice and humans.
 
The interval between thymic entry of multi-
potent bone marrow lymphoid progenitors
and thymic export of mature 
 
   
 
CD4
 
  
 
and
CD8
 
  
 
T lymphocytes requires passage through
multiple quality control checkpoints. Only those
progenitors successful in producing machinery
required for progression will receive survival
signals at each checkpoint. Although early T
lymphocyte progenitors lack surface expres-
sion of CD4 and CD8 (double negative
[DN]), their maturation can be tracked by
stage-specific changes in surface expression of
CD25 and CD44. The population advances
from the DN1 (CD44
 
  
 
CD25
 
 
 
) to DN2
(CD44
 
  
 
CD25
 
 
 
) to DN3 (CD44
 
  
 
CD25
 
 
 
)
and finally to the DN4 (CD44
 
  
 
CD25
 
 
 
) stage
(1). Deposition of an intact pre-TCR com-
plex, consisting of a productively rearranged
TCR
 
  
 
chain, the invariant pre-TCR
 
  
 
(pT
 
 
 
)
chain, and CD3 signaling chains, on the sur-
face of DN3 thymocytes, is absolutely essential
for completion of the 
 
   
 
T lymphocyte devel-
opmental program. 
 
   
 
T lymphocyte differ-
entiation halts at the DN3 stage in mice lack-
ing pT
 
 
 
, TCR
 
 
 
, CD3
 
 
 
, or CD3
 
  
 
(2).
In addition to its role in “selecting” for
further development exclusively those progen-
itors containing a productive TCR
 
  
 
rearrange-
ment, driving entry into the cell cycle, pre-
venting further rearrangement of TCR
 
  
 
loci,
and down-regulating surface expression of
CD25, pre-TCR signaling is essential for sur-
vival of 
 
   
 
T lymphocyte progenitors (2).
Analyses of mice unable to generate intact pre-
TCR complexes (
 
RAG
 
 
 
/
 
 
 
,
 
 CD3
 
 
 
 
 
/
 
 
 
,
 
 SCID
 
)
revealed large increases in the proportion of
DN thymocytes expressing an apoptotic sur-
face phenotype, thereby linking the pre-TCR
to thymocyte survival (3). Complementation
with cytoplasmic tail mutant pT
 
  
 
molecules
(4) or with a TCR
 
  
 
molecule (5) failed to rec-
tify the survival defect in the DN compart-
ment of 
 
pT
 
 
 
    
 
mice, implicating specifically
the pT
 
  
 
component as crucial for pre-TCR–
induced survival signals.
The prevalence of NF-
 
 
 
B consensus sites
among cis-elements controlling the expression
of multiple antiapoptotic genes (for review see
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reference 6), in combination with the definitive placement
of NF-
 
 
 
B as a distal effector of pre-TCR signaling (7, 8), es-
tablishes an indirect association between the pre-TCR and
the survival of developing thymocytes. The search for distal
mediators of pre-TCR–induced survival has met with little
success. The 
 
  
 
selection process proceeds normally in pro-
genitors lacking pro-survival BCL-2 family members BCL-2
or BCL-x
 
L 
 
(9, 10), and neither BCL-2 nor BCL-x
 
L 
 
trans-
genes restore 
 
   
 
T lymphocyte development in pre-TCR–
deficient mice (11–13). T lymphocyte progenitors lacking
the pro-survival Bcl-2 family member MCL-1 fail to progress
through the DN2 to DN3 developmental transition, impli-
cating MCL-1 as a crucial mediator of early cytokine-derived,
rather than later pre-TCR–derived, survival signals (14).
Further refuting a critical role for BCL-2 is the observation
that post-
 
  
 
selection thymocytes contain lower levels of Bcl-2
protein than those that have not yet entered 
 
  
 
selection (15).
However, a recent report presented conflicting evidence,
suggesting that BCL-2 expression is induced by the pre-
TCR in vitro (16).
Similarly, very little is known about the signaling path-
ways inducing death in pre-TCR
 
  
 
thymocytes. The initial
suggestion that the Fas-induced death pathway is essential for
pre–T cell death has been challenged by recent studies of
Newton et al. (17), in which the thymocyte profiles of
 
RAG-1
 
   
 
lpr
 
 mice were found to be similar to those of their
 
RAG-1
 
    
 
littermates. Fas is a member of the TNF receptor
family, whose members interact via their death domains with
cytoplasmic adaptors including FADD and TRADD (18).
The same investigators have shown that 
 
RAG-1
 
   
 
FADD
 
   
 
pre–T cells differentiate and reach the double positive (DP)
stage (17). These important observations suggested that
FADD could be essential for the transduction of death signal
within pre–T cells and fueled the search for an active pre-
TCR–dependent mechanism of cell death inhibition.
In this report, we direct our search toward antiapoptotic
genes potentially targeted by pre-TCR–induced NF-
 
 
 
B
transcription factors. We identify the pro-survival A1 gene
as a direct transcriptional target of both pre-TCR and NF-
 
 
 
B. Moreover, we connect transcriptional activation of A1
to PLC
 
 
 
, mobilization of Ca
 
2
 
 
 
, and activation of protein
kinase C (PKC) kinases. We also show that A1 expression
inhibits pre–T cell death by suppressing the activation of the
effector caspase-3. Finally, we show that A1 is up-regulated
in both human and mouse pre–T cell leukemias, making it a
possible target of the transformation event. Our observa-
tions suggest that through NF-
 
 
 
B activation and A1 expres-
sion, the pre-TCR ensures the promotion of physiological
T cell development.
 
RESULTS
Pre-TCR–nonexpressing cells die due to the activation of 
effector caspase-3
 
Evidence definitively demonstrating pre-TCR–mediated
prevention of imminent apoptosis has not been documented.
Here, we addressed this issue both in vivo and in vitro. The
percentage of proapoptotic, annexin V
 
  
 
thymocytes was sig-
nificantly larger in mice lacking pre-TCR components
 
(pT
 
 
 
   
 
,
 
 RAG-1
 
   
 
)
 
 than in their WT counterparts (Fig. 1
A). To demonstrate that pre-TCR expression provides a
survival advantage, sorted pre-TCR
 
  
 
DN3 
 
RAG-1
 
    
 
and
pre-TCR
 
  
 
DN4 WT thymocytes were cultured in a low
concentration of 1 ng/ml IL-7. As evident from Fig. 1 B,
pre-TCR–deficient cells die at a significantly higher rate
(Fig. 1 B). Similar results were obtained in the absence of
IL-7 (not depicted).
To gain insight into the mechanism of this cell death, we
analyzed activation of the distal effector caspase-3 in apoptotic
thymocytes. Using a fluorescently labeled antibody specific
for the active form of caspase-3, we detected activation of cas-
pase-3 specifically in the pre-TCR
 
  
 
DN3 subset of 
 
RAG-1
 
   
 
thymocytes ex vivo (Fig. 1 C). As receptors for prosurvival
cytokines IL-7 and stem cell factor are down-regulated at the
DN4 stage, these cells do not receive any pre-TCR–indepen-
dent survival signals. To further support these observations
and to increase the sensitivity of detection of active caspase-3,
Figure 1. Pre-TCR  thymocytes die by apoptosis due to caspase-3 
activation. (A) Percentage of thymocytes binding annexin V in the 
CD4 8  lineage  compartment of WT, Rag-1 / , and pT  /  thymi. (B) In 
vitro pre–T cell survival. Pre-TCR  (hatched bars) and pre-TCR  (solid bars) 
CD4 8  lineage  thymocytes were cultured in the absence of exogenous 
factors. Survival rates were determined by annexin V staining at the indi-
cated time points. (C) Flow cytometric detection of caspase-3 activation. 
The left plot illustrates the CD25/CD44 surface profile of Rag-1 /  thy-
mocytes. The right dot plots illustrate caspase-3 activation within indi-
cated cellular compartments. (D) Activation of caspase-3 in Rag-1 /  
thymocytes is down-regulated upon anti-CD3  injection. Positive (WT 
fibroblasts treated with brefeldin A) and negative (caspase-3 /  fibroblasts 
treated with brefeldin A) controls are included. Blots were reprobed with 
anti-actin as a loading control. 
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we probed 
 
RAG-1
 
    
 
thymocyte lysates with a second anti-
body specific for the activated (cleaved) form of caspase-3.
The activation of caspase-3 observed in this system was com-
parable to that induced by in vitro treatment of mouse em-
bryonic fibroblasts with brefeldin A (Fig. 1 D). Mimicking
pre-TCR signaling by CD3
 
  
 
cross-linking relieved the DN3
block of 
 
RAG-1
 
    
 
thymocytes (7) and decreased caspase-3
activity in these cells, adding one more piece of evidence di-
rectly connecting pre-TCR signaling with thymocyte survival
(Fig. 1 D). An identical pattern of activation was also seen for
the effector caspase 9 (unpublished data).
BCL-2, MCL-1, and BCL-xL are not targets of the pre-TCR
Conflicting reports described the roles of BCL-2 and BCL-
xL in pre–T cell death, and recent data indicated that yet an-
other antiapoptotic BCL-2 family member, MCL-1, may
regulate survival of thymocytes at an earlier, cytokine-medi-
ated stage (14). To test whether pre-TCR signaling induces
expression of these prosurvival factors, we performed real-
time RT-PCR analysis using cDNA isolated from sorted
DN3, DN4, and DP thymocytes. As evident from Fig. 2,
none of these factors were induced by the pre-TCR. MCL-1
expression was high in DN3 cells. In agreement with pre-
vious reports, it decreased in DN4 and peaked again at the
DP stage. BCL-xL expression was low in both DN3 and
DN4 populations, peaking at the DP stage. BCL-2 expres-
sion seemed to be actively down-regulated upon pre-TCR
expression, reaching a minimum at the DP stage (Fig. 2 A).
Similar results showing no up-regulation of BCL-xL and
MCL-1 and a down-regulation of BCL-2 were obtained us-
ing two distinct pre-TCR  (SCIET27 and LR2) and pre-
TCR  (SCB29 and LR2wtpT ) cell lines (Fig. 2 B and un-
published data; reference 19).
A1 gene is a direct target of pre-TCR signaling
After excluding BCL-2, BCL-xL, and MCL-1 as antiapop-
totic pre-TCR transcriptional targets, we focused specifically
on antiapoptotic BCL2 family genes whose cis regulatory el-
ements contain NF- B consensus sites. The BCL2A1 (A1)
gene cluster (three A1 genes: A1a, A1b, and A1d; one
pseudogene: A1c) fit this description. Expression of this NF-
 B–responsive gene cluster is induced by inflammatory stim-
uli, B cell receptor stimulation, and CD40 signaling (20–22).
Figure 2. BCL-2, BCL-xL, and MCL-1 are not induced by pre-TCR 
signaling. (A) Quantitative real-time RT-PCR analysis of BCL-2, MCL-1, 
and BCL-xL expression in the indicated thymocyte subsets. (B) Quantita-
tive RT-PCR analysis of gene expression in the LR2 and LR2wtpT  cell 
lines. Actin expression was used to normalize gene expression.
Figure 3. Pre-TCR signaling induces A1 expression both in vivo and in 
vitro. (A) Semiquantitative and real-time RT-PCR analysis of A1 expression in 
ex vivo thymocyte subsets. (B) Semiquantitative PCR analysis of A1 expression 
in pre-TCR  (lane 2, SCB29; lane 4, LR2-WTpT ) and pre-TCR  (lane 1, 
SCIET27; lane 3, LR2) cell lines. (C) Pre-TCR complexes containing truncated 
pT  chains fail to induce A1 expression. Semiquantitative PCR-quantitated A1 
expression in LR2 cells expressing (lane 1) no pT  chain, (lane 2) a WT pT  
chain, (lane 3) a pT  chain lacking its entire cytoplasmic domain, or (lane 4) a 
pT  chain lacking its proline-rich domains. (D) Isoform-specific pattern of A1 
expression in DN4 pre–T cells. A1 cDNA amplified from DN thymocytes (using 
A1XhoUp1 and A1BamLow1 primers) was left nondigested (lane 1), digested 
with NsiI (lane 2), or digested with BglII (3).THE BCL2A1 GENE AS A POTENTIAL REGULATOR OF PRE–T CELL SURVIVAL | Mandal et al. 606
A1 expression protects cells from various death stimuli in-
cluding TNF-  stimulation, p53 activation, B cell receptor
triggering, and IL-3 deprivation (23–25). Our gene expres-
sion analyses identified the A1 gene cluster as a potential pre-
TCR target (Fig. 3). Sorted RAG-1    pre-TCR  DN3
thymocytes lacked A1 transcripts, whereas sorted preTCR 
WT DN4 thymocytes expressed abundant A1 transcripts.
Only after mimicking pre-TCR signaling by injection of
anti-CD3  antibody was A1 expression detected in RAG-
1    thymocytes (Fig. 3 A). These observations were repro-
duced multiple times using different primer pairs and were
confirmed by quantitative real-time PCR (Fig. 3 A). To test
whether A1 induction was a direct effect of pre-TCR signal-
ing, we compared A1 expression in pre-TCR  (SCIET27
and LR2) and pre-TCR  (SCB29 and LR2-WTpT ) pre–T
cell lines (7). SCIET27 and LR2 are parental pre-TCR 
lines. Introduction of TCR  (in SCIET) and TCR  pT 
(in LR2) results in the generation of the pre-TCR  SCB29
and LR2-WTpT  lines (5, 7). As shown in Fig. 3 B, pre-
TCR expression induced A1 expression in both cell lines.
Moreover, LR2 cell lines engineered to express truncated
forms of pT  (mutations of the cytoplasmic tail of the mole-
cule) illustrated the crucial nature of the pT  cytoplasmic tail
in pre-TCR–mediated A1 induction (Fig. 3 C). These ob-
servations are consistent with our previous report, which
showed that thymocytes expressing truncated pT   chains
underwent abnormal    selection characterized by defects
both in proliferation and in cell survival (4).
The existence of three A1 isoforms, each encoded by a
different gene, prompted us to investigate which isoforms of
A1 were expressed in pre–T cells. To this end, A1 cDNA
amplified from DN4 cells was digested with restriction en-
zymes whose recognition sites are located in isoform-specific
sequence polymorphisms (26). The enzyme NsiI was unable
to digest A1 cDNA amplified from pre–T cells (purified
DN4), indicating that A1a is either not expressed or ex-
pressed at undetectable levels in these cells. In contrast, di-
gestion with the BglI enzyme strongly suggested that A1d is
one of the major isoforms expressed in pre–T cells (Fig. 3
D). In addition to verifying these results, sequencing indi-
cated that A1b was also expressed in pre–T cells, albeit at a
level lower than that of A1d (not depicted). These observa-
tions suggest an isoform-specific pattern of A1 expression in
pre–T cells.
Activation of phospholipase C  (PLC ), Ca2 , and NF- B 
are critical for A1 induction
The above observations place A1 expression downstream of
the pre-TCR, but the signaling components connecting
pre-TCR signals with A1 induction remain unidentified.
We initially addressed the role of NF- B in pre-TCR–
induced A1 expression. As mentioned above, pre-TCR  cell
lines (SCB29 and LR2WTpT ), but not their pre-TCR–
deficient counterparts (SCIET27 and LR2), contained abun-
dant A1 transcripts. To inhibit NF- B activation in SCB29
and LR2WTpT  cell lines, we generated a retroviral vector
Figure 4. A1 is a target of the PLC -Ca2 -NF- B pathway. (A) A1 
is a transcriptional target of NF- B. Semiquantitative RT-PCR analysis of 
A1 expression in pre-TCR  cell lines after the inhibition of NF- B. In the 
absence of pre-TCR signaling, 50 ng/ml PMA plus 1  g/ml Iono treatment 
can induce A1 expression (B), as well as NF- B nuclear translocation and 
Ca2  mobilization (C). (D) Ca2  mobilization is essential for A1 transcrip-
tional induction. A1 expression was examined by semiquantitative RT-PCR 
after chelation of intracellular Ca2  by 1 mM TMB8. (E) PLC  activation is 
essential for A1 induction. A1 expression levels were examined by semi-
quantitative and real-time RT-PCR in pre-TCR  cell lines (N3T and SCB29) 
incubated with 10  M of the specific PLC  inhibitor U73122.JEM VOL. 201, February 21, 2005 607
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encoding a mutated nondegradable form of the inhibitor of
NF- B    (IKB  ; reference 8). When expressed in pre-
TCR  SCB29 and LR2WTpT  cell lines, IKB   completely
inhibited pre-TCR–induced A1 expression, suggesting an
essential role of NF-kB in pre-TCR–dependent up-regula-
tion of A1 (Fig. 4 A). These observations are consistent with
those of Voll et al. (8), who demonstrated that pre–T cell–
specific expression of an IKB   transgene (driven by the
p56lck promoter) slowed pre-TCR–driven    T lymphocyte
development.
We have previously shown that activation of PLC  and
Ca2  mobilization are essential for the transduction of pre-
TCR signals (7). To address the role of these two mediators
in pre-TCR–induced A1 expression, we used the PMA and
ionomycin (Iono), which have been shown to be able to
mimic pre-TCR signaling (7). Treatment with PMA and
Iono rapidly induced A1 expression in a pre-TCR–deficient
line (Fig. 4 B), and Rag-1    purified DN3 thymocytes (not
depicted). Because this treatment induces both Ca2  mobili-
zation as well as nuclear translocation of NF- B (Fig. 4 C),
we tested whether A1 expression depends on one or both of
these stimuli. Pretreatment of these cell lines with an endo-
plasmic reticulum Ca2  chelator, TMB-8, totally abrogated
A1 expression (Fig. 4 D) and NF- B activation (7), high-
lighting Ca2  as an essential second messenger. To test
whether A1 induction was dependent on PLC  activation,
pre-TCR  SCB29 and N3-T (a leukemic cell line that has
up-regulated A1 expression in response to Notch activation
and overexpression of the pre-TCR) cell lines were incu-
bated with the specific PLC  inhibitor U73122, which in-
hibits Ca2  signaling in pre–T cells (7). As shown in Fig. 4 E,
inhibition of PLC  activity totally blocked the ability of the
pre-TCR (and of PMA plus Iono treatment) to induce A1
expression in both cell lines. Similar results were obtained
Figure 5. PKC is essential for pre-TCR–induced A1 expression. 
(A) SCIET27 cells were infected with a retrovirus expressing constitutively 
active forms of PKC (SCI-PKC CAT) or Akt (SCI-Myr-Akt). A1 expression 
was compared with uninfected SCIET27 by RT-PCR. (B) In vitro inhibition 
of PKC activity using 1  M of the PKC inhibitor calphostin, abrogates A1 
expression induced by PMA plus Iono in SCIET27 cells. (C) Inhibition of PKC 
activity blocks normal T cell development and induces pre–T cell death in 
an OP-9-DL1 culture. WT DN2 thymocytes were cultured in the presence 
or absence of calphostin or DMSO control. Differentiation (left) and sur-
vival (right) were examined by staining with anti-CD4 and anti-CD8 anti-
bodies and annexin V. Data are representative of at least four independent 
experiments using 0.1  M calphhostin. (D and E) SCIET27 cells expressing 
PKC CAT are more resistant to irradiation- (480 rads) induced death (left) 
due to the attenuation of caspase-3 activation (right).THE BCL2A1 GENE AS A POTENTIAL REGULATOR OF PRE–T CELL SURVIVAL | Mandal et al. 608
using a third pre-TCR  cell line, LR2-WTpT  (not de-
picted). The inhibition was complete regardless of the initial
level of A1 expression.
PKC activation is essential for A1 induction and survival
PLC  activity generates both inositol triphosphate, which
initiates Ca2  mobilization, and diacylglycerol (DAG), which
activates downstream kinases such as PKC. To address the
potential role of PKC in pre-TCR–induced A1 expression,
we expressed a constitutively active form of PKC (PKC  
CAT) in pre-TCR–deficient (and thus A1 ) SCIET and
LR2 cell lines. PKC activation strongly induced A1 expres-
sion in the SCIET (Fig. 5 A) and LR2 (not depicted) cell
lines. To establish PKC specificity, we expressed an activated
(myristoylated) form of PKB/Akt (Myr-Akt), another kinase
involved in the transduction of pre-TCR signals (unpub-
lished data). As shown in Fig. 5 A, Myr-Akt failed to up-
regulate A1 expression, classifying pre-TCR–induced A1
expression as strictly dependent on PKC.
To further illustrate PKC involvement, pre-TCR 
SCIET and LR2 cells were pretreated with calphostin, a po-
tent and specific PKC inhibitor. Calphostin treatment totally
blocked PMA plus Iono–induced A1 expression in SCIET
(Fig. 5 B) and LR2 (not depicted) cell lines. To demonstrate
that PKC inhibition adversely affected pre–T cell survival and
differentiation, we used a novel in vitro culture system (27).
In this system, OP-9 stromal cells expressing the Notch
ligand Delta-1 (OP9-DL1) support thymic-independent de-
velopment of T cell progenitors. Sorted DN2 cells were cul-
tured with OP9-DL1 cells and supplemented with various
concentrations of calphostin or DMSO control. As shown in
Fig. 5 C, calphostin, but not DMSO treatment, significantly
blocked progression to the DP stage of T cell development.
This effect was due to decreased survival, as  85% of the
calphostin-treated cells were proapoptotic. Also, the majority
(60%) of calphostin-treated cells remained CD4 8 CD25 
(not depicted). To directly connect PKC activation and A1
expression to pre–T cell survival, we compared survival ki-
netics of irradiated (400 rads) pre-TCR–deficient SCIET27
cells expressing either PKC CAT-EGFP or EGFP. PKC  
CAT expression provided a significant protection from apop-
tosis (Fig. 5 D), which correlated with the ability of PKC to
prevent caspase-3 activation (Fig. 5 E). Identical results were
obtained using a second pre-TCR  line (LR2).
A1 as a regulator of pre–T cell survival
To study the function of A1 in the promotion of pre–T cell
survival, we ectopically expressed A1d (the most commonly
expressed A1 isoform) in SCIET pre–T cells (4). A1d and
EGFP were expressed on a single transcript after infection
with a bicistronic A1-IRES-EGFP retrovirus. This retrovi-
rally encoded A1 protein was properly expressed and tar-
geted to the mitochondria (not depicted). As pre–T cells sus-
tain DNA breaks generated during ongoing recombination
at their TCR loci, we investigated A1’s ability to inhibit
death induced by DNA-damaging ultraviolet irradiation.
A1d expression efficiently suppressed irradiation-induced
cell death in SCIET (Fig. 6 A) and LR2 (not depicted) pre–
T cells. Mechanistically, the inhibition of cell death resulted
from an A1-mediated reduction in caspase-3 activation (Fig.
Figure 6. A1 induces pre–T cell survival. SCIET27 cells expressing 
EGFP (black dashed and gray lines) or A1-EGFP (black line) were irradi-
ated (gray, control; black, A1-expressing) and left in culture for the indi-
cated time periods. Survival was detected using annexin V labeling (A). 
Caspase-3 activation was measured 4 h after irradiation (B). Retroviral 
expression of A1 induces survival and differentiation of Rag-1 /  pre-TCR  
thymocytes. Ratios of infected (A1 ) and uninfected (A1 ) RAG-1 /  
thymocytes at the indicated time points after injection into Rag-2 /  c /  
hosts (C). Differentiation of A1  and A1  thymocytes was analyzed 6 wk 
after injection by surface staining with antibodies specific for CD4, CD8, 
and CD25 (D). (E) A1 expression does not alter differentiation of WT thy-
mocytes. CD4/CD8 surface profiles of WT thymocytes infected with A1-
IRES-EGFP or IRES-EGFP retroviruses were examined 3 wk after injection 
into Rag-2 /  c /  hosts.JEM VOL. 201, February 21, 2005 609
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6 B). Similar results were obtained with dexamethasone
treatment as a death stimulus (not depicted).
To support these in vitro observations using primary
thymocytes, we infected lineage- (CD19, Ter-119, Gr-1,
NK1.1,    TCR,    TCR, Mac-1, CD11c) negative bone
marrow progenitors sorted from (Ly5.1 ) RAG-1 /  animals
with the A1d-IRES-EGFP retrovirus. Alymphoid irradiated
(350 rads) Rag /  c /  (Ly5.2 ) hosts were injected with the
Ly5.1  A1-infected bone marrow cells. Thymic reconstitu-
tion was analyzed at various time intervals after cell transfer.
Retroviral A1d bestowed a significant survival advantage
upon developing thymocytes (Fig. 6 C). Although injected at
a 40:60 ratio of EGFP A1 /EGFP A1 , 3 wk’s time re-
versed this ratio to 65:35 (Fig. 6 C). Four additional weeks
resulted in a near absence of EGFP  A1  cells in reconstituted
thymi, suggesting that EGFP A1  thymocytes out-competed
their coinjected EGFP  A1  counterparts. Interestingly, de-
spite their lack of a pre-TCR complex, these RAG-1 / 
EGFP A1   thymocytes displayed signs of differentiation.
More than half of the cells up-regulated CD4 and CD8 core-
ceptor surface expression (Fig. 6 D). Importantly, annexin
V staining revealed little apoptosis among the A1 EGFP 
population  and high percentages of apoptotic cells in the
EGFP  population (not depicted). No A1 EGFP  cells were
detected in the periphery, due to the inability of the RAG-
1 /  cells to express selectable TCRs (not depicted). These
results suggest that A1 expression, which is physiologically
triggered by pre-TCR signaling, induces pre–T cell survival
and ensures differentiation. To illustrate that A1 expression
does not affect the physiological progression of T lymphocyte
development, we repeated the above reconstitution experi-
ments using bone marrow progenitors sorted from WT mice.
No difference was apparent between the differentiation kinetics
of WT A1 EGFP  and WT A1 EGFP  progenitors when
Figure 7. A1 knockdown impairs pre–T cell survival in vitro. 
(A) Effective A1 silencing in pre–T cells. Pre-TCR  N3T cells were infected 
with the Banshee-EGFP retroviral vector alone (siEGFP) or Banshee-EGFP 
retroviruses encoding one of three independent siRNA complexes specific 
for A1 (A1-A, A1-C, and A1-D). Semiquantitative and real-time RT-PCR 
analyses illustrate the efficiency of A1 silencing using each siRNA. (B and 
C) A1 silencing affects survival of pre-TCR  (N3T), but not pre-TCR  (LR2), 
cells. Uninfected N3T or LR2 cells (EGFP ) were mixed at the indicated 
ratio with N3T or LR2 cells infected with Banshee-EGFP (EGFP) or Banshee-
EGFP vectors encoding siA1-A, siA1-C, or siA1-D complexes. Alterations 
in the ratio of uninfected (EGFP ) to infected (EGFP ) cells were recorded 
at the indicated time points. This experiment is a representative of four 
independent experiments. (D) Retrovirally expressed siRNA complexes do 
not induce IFN response genes. Real-time PCR expression analysis of 
IFIT-1 and IRF-7 IFN response genes in cell lines infected with the indi-
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injected in age- and sex-matched hosts (Fig. 6 E). These ob-
servations are consistent with the recently reported normal T
cell development in thymi of mice expressing an A1a trans-
gene driven by a p56Lck promoter (28).
To demonstrate that A1 is necessary for pre–T cell sur-
vival, we studied pre–T cell survival in the absence of A1 ex-
pression. The existence of three independent A1 isoforms
precludes gene-targeting approaches. Multiple consecutive
targeting steps would be necessary, as the genes encoding the
three A1 isoforms are not all clustered together on chromo-
some 9. In addition, the significant conservation in both
exon and intron sequences shared among the A1 isoforms
would make design of gene-targeting vectors extremely dif-
ficult. Therefore, we used stable RNA interference to knock
down A1 expression in a T lymphocyte–specific manner. To
eliminate concern about redundancy among A1 isoforms,
we generated short interfering RNAs (siRNAs) capable of
knocking down expression of all three A1 isoforms. These
siRNAs were expressed using a self-inactivating retrovirus
carrying a U6 Pol-II promoter able to drive expression of
siRNAs. We tested three different siRNAs, and achieved
optimal interference with siRNA-A (Fig. 7 A). Real-time
RT-PCR analysis showed silencing efficiency at 75–85%
(Fig. 7 A). The effects of A1 deficiency on pre-TCR func-
tion were assessed in the pre-TCR  N3-T cell line (Fig. 8
D). N3-T cells expressing each of the three different siRNAs
(EGFP ) were mixed at a ratio of 50:50 with EGFP N3-T
cells. As shown in Fig. 7 B, N3-T cells expressing A1-spe-
cific siRNAs exhibited a survival disadvantage, proportional
in severity to the efficiency of A1 knockdown. This defect is
due to loss of survival, as at any given time of the culture, the
proportion of cells binding annexin V was two to four times
higher in the population expressing A1-siRNA (siRNA-A)
when compared with cells expressing a control EGFP-
siRNA (not depicted). No significant differences in cell cy-
cle progression were observed between cells expressing
EGFP-siRNA and A1-siRNA constructs (not depicted).
When infected with the same siRNAs, neither 3T3, 293T,
nor LR2 cells (Fig. 7 C) showed survival defects, suggesting
that the effect of A1 knockdown is specific to cells that spe-
Figure 8. A1 is a target of T cell transformation both in mouse and 
man. (A) Relative expression levels of pT  and specific T cell differentia-
tion marker genes (rows) across 43 human T cell leukemia samples (columns). 
Normalized gene expression levels are represented in colors. Groups of 
samples were identified (top) according to the expression of the indicated 
T cell differentiation markers. Expression of pT  clearly correlates with a 
group of genes including p56lck, CD3 , CD4, and CD8. pT  expression is 
completely absent in early CD34  pro–T cell leukemias. This is a pictorial 
representation of the expression levels with no intention to represent spe-
cific gene expression levels. (B) A1 and BCL-2 expression was quantitated 
by real-time RT-PCR analysis in selected representative T-ALL samples. 
BCL2 and A1 expression were compared in pro–T cell and cortical T-ALL 
samples using a Wilcoxon rank sum test, showing a significant correlation 
of BCL2 expression with pro–T T-ALL samples and of A1 expression with 
cortical T-ALL samples. (C) Surface phenotype characterization of a murine 
T cell leukemia line (N3T). (D) Expression of A1 in N3T cells. Real-time 
RT-PCR comparison between N3T, DN3, DN4, SCIET27 (our expression 
base), and LR2 cells.JEM VOL. 201, February 21, 2005 611
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cifically up-regulate A1 due to pre-TCR overexpression
(Fig. 8). Moreover, BCL-xL and BCL-2 expression re-
mained unaltered in N3-T cells that undergo apoptosis due
to the A1 deficiency, suggesting that these two genes are not
involved in the maintenance of N3-T cell survival (unpub-
lished data).
To exclude nonspecific siRNA effects due to potential
IFN responses, we have selected two well-characterized IFN-
responsive genes and studied their expression in pre–T cells
expressing our siRNAs (29). There was no specific up-regu-
lation of either IFN-induced protein 1 or IFN regulatory fac-
tor 7 in our siRNA-expressing pre–T cells (Fig. 7 D).
A1 expression is a molecular target of 
pre–T cell transformation
Deregulated pre-TCR signaling triggers aggressive pre–T
cell leukemia in mice (30, 31). Genes encoding molecules
involved in pre-TCR signaling (p56Lck, ZAP-70, TCR ,
CD3 , and cyclin D3) are overexpressed in human T cell
acute leukemias (T-ALLs) arising from early to late cortical
thymocytes, which are characterized by the expression of the
oncogenes HOX-11  and TAL-1 . Thus, it is conceivable
that the survival advantage conferred by pre-TCR–induced
antiapoptotic genes like A1 may contribute to the transfor-
mation process (not as a bona fide oncogene but as a target
of the transformation event). To connect pre-TCR and A1
expression to a precise window of thymocyte differentiation,
we used the patient expression profile data presented by Fer-
rando et al. (32) to analyze the expression of pT  within the
three different clusters of human T-ALL cases. As shown in
Fig. 8 A, pT  expression is seen primarily within Hox-11 
early cortical thymocytes, rather than within LYL1  CD34 
progenitors or TAL-1  mature T cells. To link A1 expres-
sion with induction of T cell leukemia, we selected repre-
sentative cases from each cluster of human T-ALL cases and
performed quantitative real-time RT-PCR. As evident from
Fig. 8 B, A1 expression correlated only with HOX-11 or
TAL-1–expressing samples. This is consistent with the no-
tion that A1 is induced only after pre-TCR signaling and
peaks at the DP stage of development. Interestingly, BCL-2
expression peaked early in development (in CD3  CD34 
samples) and declined after the appearance of the pre-TCR
and A1 (Fig. 8 B). This observation is consistent with our
previous expression analysis of A1 and BCL-2 during physi-
ological T cell development (Figs. 2 and 3).
To complement these studies, we analyzed A1 expres-
sion in a mouse model of T cell leukemia. In this model, in-
troduced by Bellavia et al. (33), T cell–specific expression of
a constitutively active form of Notch-3 induces malignant
transformation of thymocytes. We have chosen Notch-3 be-
cause “nearest neighbor” analysis of the T-ALL database
used above had shown that pT  and Notch-3 share a strik-
ingly identical expression profile (unpublished data). The
Notch transformation is strictly dependent on pre-TCR sig-
naling (31). N3-T, an immature HSAhi CD25lo CD4  CD8 
cell line derived from the thymus of a Notch-3 transgenic
animal, most likely represents the pre-TCR  DN3 to DN4
transitional stage of thymocyte development (Fig. 8 C; refer-
ence 33). Surface pre-TCR levels on N3-T cells are even
higher than those on WT DN4 cells (Fig. 8 C). In line with
our human T-ALL studies, N3-T cells expressed A1 at levels
significantly higher that those in WT DN4 thymocytes or in
DN cell lines (Fig. 8 D). As shown in Fig. 7 B, A1 is crucial
for in vitro survival of N3-T cells, as A1 “knockdown” con-
ferred a significant survival disadvantage.
DISCUSSION
The identification of NF- B as a pre-TCR target (7, 8) and
the phenotype of transgenic mice expressing an inhibitor of
the NF- B pathway (I B  ) specifically in pre–T cells (8)
initiated our search for NF- B–responsive downstream ef-
fectors regulating pre–T cell survival. Together with impor-
tant reports directly connecting A1 transcription to NF- B
activation (34, 35), the recent observation of endogenous
c-Rel binding directly to cis elements regulating A1 gene
expression (36) directed our search toward A1. Here, we
show that A1 expression is directly induced by the pre-
TCR. Moreover, A1 appears to be the only antiapoptotic
gene induced during   selection, as neither members of the
BCL2 family nor members of the IAP family are induced by
the pre-TCR (Fig. 2 and unpublished data).
One can argue, however, that the data presented are
equally consistent with the notion that A1 is a Notch target,
as Notch can also activate the NF-kB pathway. This is an in-
triguing possibility that could provide insights in the mecha-
nism of cooperation between Notch and the pre-TCR (37).
However, multiple lines of evidence argue against this sce-
nario and highlight the unique ability of the pre-TCR to
regulate A1 expression. Initially, expression of activated
forms of Notch-1 (N1-IC) in pre-TCR  lines (SCIET27
and LR2) failed to up-regulate A1 expression (unpublished
data). Moreover, specific mutation of the pre-TCR (cyto-
plasmic truncation) blocked any A1 expression without af-
fecting Notch expression (Fig. 3). Finally, DN thymocytes
from pT  /  mice that overexpress active Notch-3 show
activation neither of PKC nor of NF- B, suggesting that the
pre-TCR, rather than Notch, regulates the activity of this
pathway in developing pre–T cells (unpublished data).
Why the pre-TCR uses A1 rather than the prototypical
antiapoptotic molecules BCL-2 or BCL-xL is not yet under-
stood. However, overexpression of BCL-2 is unable to re-
store normal developmental progression in pre-TCR–defi-
cient pT     (unpublished data) or RAG-1 /  mice (11).
The preferential use of A1 might be due to the antiprolifera-
tive properties ascribed to BCL-2. Introduction of a BCL-2
transgene into WT mice actually impaired the proliferation of
TCR -selected DN4 thymocytes (38). It was suggested that
this antiproliferative effect depends on the ability of BCL-2 to
bind to and sequester the calcium-dependent calcineurin
phosphatase, thereby inhibiting NF-AT nuclear translocation
and activation (39, 40). This interaction between BCL-2 and
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of BCL-2, which are also present in BCL-xL and MCL-1. In
contrast, all three A1 genes lack these conserved calcineurin
interaction sites (unpublished data). Thus, BCL-2, BCL-xL,
and MCL-1, but not A1, may prevent NF-AT activation,
which is important for pre-TCR function (7). Consistent
with this notion, Gonzalez et al. (28) recently have shown
that overexpression of A1, but not BCL-2, allowed normal
proliferation of mature activated T lymphocytes.
Our studies underline the role of PKC as an intermediate
transducer of pre-TCR signals. PKC isoenzymes are grouped
into two major subfamilies. The activation of conventional
PKCs (cPKCs) as well as novel PKCs (nPKCs) typically in-
volves recruitment to membranes and interaction with or al-
losteric activation by DAG. Ca2  binding is an essential re-
quirement for cPKCs, but not nPKCs (41). PKC , cPKC,
PKC , and nPKC, are the major PKCs expressed in thy-
mocytes (41). In our experiments, PMA plus Iono treatment
induced A1 expression in pre-TCR  cells, whereas Iono
alone did not. Also, PMA plus Iono in the presence of the
ER Ca2  chelator, TMB-8, induced neither A1 expression
nor NF- B activation. As induction of NF- B activation and
A1 expression required both PMA and Iono, it is tempting to
suggest that pre-TCR signaling activates PLC , which mobi-
lizes Ca2 , which, along with DAG, activates only cPKC
isoenzymes (i.e., PKC ). Consistent with this view is the lack
of a pre-TCR–dependent phenotype in mice lacking the
PKC  isoenzyme (42). However, we cannot exclude that
PKC , although not absolutely essential, plays a secondary
role amplifying PKC -mediated signals to the nucleus.
A recent study illustrated PKC’s importance in pre-TCR–
mediated allelic exclusion at the TCR  locus (43). Separate
work demonstrated that although activation of PKC can par-
tially restore DN to DP transition in RAG-1 /  mice, it is not
able to drive thymocyte expansion (a phenotype identical to
those of mice reconstituted with A1  RAG-1 /  progenitors,
presented here; reference 37). Perhaps the bifurcation in pre-
TCR signaling that occurs downstream of the LAT/SLP-76
complex leads in one direction toward PKC-independent sig-
nals inducing thymocyte expansion (Raf/Ras, Akt) and in the
other direction toward PKC-dependent signals establishing
TCR  allelic exclusion and ensuring survival.
The critical role of A1 in transmitting pre-TCR–induced
antiapoptotic signals and the previous correlation of de-
regulated pre-TCR signaling with T cell leukemia, prompted
us to analyze the patterns of A1 expression in human T-ALL
cases and in a Notch-induced model of mouse leukemia. We
found a unique correlation between A1 expression and re-
ceipt of pre-TCR signals and have shown that A1 knock-
down of A1 expression can affect survival of a pre–T cell
leukemic line. We recently identified cyclin D3 as an essen-
tial mediator of pre-TCR–induced proliferative signals and
suggested that cyclin D3 expression was essential for trans-
formation of pre–T cells (44). A1 overexpression may coop-
erate with cyclin D3 to provide a survival signal rendering
transformed pre–T cells resistant to apoptotic signals. These
findings could have clinical importance because TAL1  leu-
kemias are resistant to chemotherapy potentially due to the
overexpression of the antiapoptotic A1 (32).
The pre-TCR possesses the unique ability to override
cell intrinsic (i.e., DNA damage-induced) and extrinsic (i.e.,
death receptor–induced) apoptotic stimuli. We describe a
novel mechanism by which the pre-TCR meets this respon-
sibility, namely transcriptional induction of A1. Our data do
not exclude the possibility that the pre-TCR may use addi-
tional mechanisms of cell death inhibition or that non-pre-
TCR–induced antiapoptotic factors (like BCL-xL or BCL-2)
could assist A1 in the regulation of cell survival. Indeed, the
pre-TCR could directly down-regulate the transcription of
proapoptotic genes or it could regulate the stability and deg-
radation of proapoptotic molecules at a posttranslational
level, via phoshporylation and/or ubiquitination. These po-
tential alternative regulation mechanisms as well as the extent
of functional cooperation of A1 with other antiapoptotic
genes during   selection are currently under investigation.
MATERIALS AND METHODS
Mice and cell lines. C57BL/6, pT    , and RAG-2 /  mice were kept in
the sterile Carlson Barrier animal facility. All animal experiments were per-
formed in accordance to the guidelines of the Institutional Animal Care and
Use Committee of the university. For pre-TCR mimicking experiments,
RAG-2 /  mice were injected with anti-CD3 as described previously (7). All
cell lines were cultured in RPMI containing 10% fetal bovine serum (Sigma-
Aldrich), 1% penicillin/streptomycin, n and 0.1%  -mercaptoethanol (GIBCO
BRL). The caspase-3 /  fibroblasts were as described previously (45).
Patient material. Samples of cryopreserved lymphoblasts from children and
young adults treated in Total Therapy studies XI–XIII at St. Jude Children’s
Research Hospital were obtained with informed consent at the time of diag-
nosis before any chemotherapy was given. All protocols and consent forms
were approved by the hospital’s institutional review board, and informed con-
sent was obtained from parents, guardians, or patients (as appropriate).
RT-PCR and quantitative RT-PCR. Total cellular RNA was isolated
by using an RNeasy kit (QIAGEN). Each cDNA template was made from
total RNA using the Superscript II-RT kit (Invitrogen). PCR reactions
were performed with RedTaq (Sigma-Aldrich). Transcripts of all murine
A1 isoforms were detected using two primer pairs: forward-1, 5 -cat-
taactggggaaggattgtgac-3 , reverse-2 5 -gcagaaaagtcagccagccagatt-3 , and for-
ward-2, 5 -tcatgcatatccactccctggctgagc- 3 , reverse-2, 5 -gtcctgtcatctgca-
gaaaagtcagcc-3 . Murine   actin transcripts were detected using 5 -tggaatc-
ctgtggcatccatgaaac-3   as the forward primer and 5 -taaaacgcagctcagtaa-
cagtccg-3  as the reverse primer. For detection of antiapoptotic genes we
used the following: BCL2F, 5 -atcttctccttccagcct-3 ; BCL2R, 5 -tcattcaac-
cagacatgc-3 ; MCL-1F, 5 -agagcgctggagaccctg-3 ; MCL-1R, 5 -ctatcttatta-
gatatgccagacc-3 ; BCL-xL forward, 5 -tggagtcagtttagtgatgtc-3 ; and BCL-
xL reverse, 5 -gctcgattgttcccgtagag-3 .
Quantitative analysis of cDNA amplification was assessed by incorpora-
tion of SYBR Green into dsDNA. PCR reactions containing 1 ug cDNA
template, 0.5  M each of the primers, and SYBR Green PCR Master Mix
(Applied Biosystems) were performed in a total volume of 25  l. Gene ex-
pression was analyzed using the ABI PRISM 7700 Sequence Detector (Ap-
plied Biosystems) and ABI Prism Sequence Detection Software version
1.9.1 (Applied Biosystems). Normalization of samples was performed by di-
viding the value of the unknown gene by the value of the endogenous ref-
erence genes (  actin). Quadruplicate reactions were performed using all
cDNA samples. For the real-time PCR analysis using human leukemic sam-
ples, total RNA from cryopreserved lymphoblasts was extracted using the
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The cDNA was analyzed by quantitative PCR using the SYBR Green
RT-PCR Core Reagents (Applied Biosystems). Quantitative PCR analyses
were performed with an ABI PRISM 7700 Sequence Detection System in-
strument (Applied Biosystems) in a total volume of 25  l. Relative expres-
sion was calculated for each gene using the  CT method. Expression levels
were normalized according to expression of GAPDH housekeeping gene.
We used the following primers: GAPDH forward, 5 -gaaggtgaaggtcggagt-
3 ; GAPDH reverse, 5 -gaagaggtgatgggatttct-3 ; BCL2 forward, 5 -gattgtg-
gccttctttgagttcg-3 ; BCL2 reverse, 5 -cgtacagttccacaaaggcatcc-3 ; BCL2-A1
forward, 5 -ccccggatgtggatacctataagg-3 ; and BCL2-A1 reverse 5 -attttc-
ccagcctccgttttgc-3 .
Microarray analysis. Expression data from 43 T cell lymphoblastic leuke-
mia samples reported by Yeoh et al. (46). Classification, subtype discovery,
and prediction of outcome in pediatric acute lymphoblastic leukemia by
gene expression profiling was also according to Yeoh et al. (46). Normaliza-
tion of global fluorescence differences across arrays and calculation of gene
expression values were preformed using dChip (http://www.dchip.org).
Normalization of relative expression levels across all 43 samples and visual-
ization of selected T cell differentiation marker genes (TCR-related genes)
were performed using Gene Cluster (http://www.broad.mit.edu/cancer/
software/genecluster2/gc2.html). Additional information concerning the sam-
ples and the microarray analysis can be found at: http://www.stjuderesearch.
org/data/ALL1.
Flow cytometric analysis and cell sorting. Anti-CD4 (L3T4), CD8
(53-6.7), CD25 (3C7), CD44 (IM7), B220 (RA3-6B2), CD11c (HL3),
NK1.1 (PK136), TCR  (H57-597), TER-119 (TER-119), Mac-1 (M1/70),
Gr-1 (RB6-8C5), and heat stable antigen (M1/69) mAbs were from BD Bio-
sciences. These mAbs were directly coupled to FITC, PE, CYC, APC, or bi-
otin. Surface marker expression on thymocytes and peripheral T cells was vi-
sualized using a FACSCalibur (Becton Dickinson) and analyzed with Flow-Jo
and CELLQuest software. Cell sorting was performed using a Mo-Flo (Dako-
Cytomation). DN thymocytes were isolated as described by Aifantis et al. (7).
Retroviral constructs and progenitor infections. MigR1 (30) and a
previously described moloney murine leukemia virus–based retroviral vec-
tor (4) were used for retroviral transduction experiments. PKC CAT (a
constitutively active form of PKC) constructs were cloned upstream of the
MigR1 IRES-GFP cassette (37). Mouse A1d cDNA was amplified from
WT thymocyte cDNA using the following primers: A1XhoUp1, 5 -gcctc-
gagcaacagcctccagatatgattaggg-3  and A1BamLow1, 5 -cggatcctaaccattctc-
ctgggagccaagg-3 . After amplification, the PCR product was sequenced and
cloned in the XhoI–BamHI sites of the moloney murine leukemia virus–
based vector upstream of an IRES-EGFP cassette (4). Retroviral superna-
tants were generated as described previously (47).
Retrovirally expressed A1 siRNA. We have used the Banshee-EGFP
(48) retroviral vector (provided by J. Alberola-Ila, California Institute of
Technology, Pasadena, CA) to express small interfering RNAs in pre–T
cells. The cloning procedure has been described by Hernandez-Hoyos et al.
(48). The following siRNA sequences were used: siA1-A, 5 -ggaaat-
gctctttctcctcaa-3 ; siA1-C, 5 -gagcagattgccctggatgta-3 ; and siA1-D, 5 -
ggagaatggatacggcggaat-3 . After cloning, sequencing was used to ensure the
insertion of the correct sequence. Concentrated retrovirus was generated as
described above.
T cell differentiation in OP9-DL1 culture. 2     103  sorted DN2 or
DN3 thymocytes were placed in each well of a 24-well tissue culture plate
containing a confluent monolayer of OP9-DL1 cells in DMEM (Life Tech-
nologies) supplemented with 15% FCS, penicillin/streptomycin, L-gluta-
mine, and 5 ng/ml rIL-7 and rFlt3L (PeproTech) as described previously
(27). The PKC inhibitor calphostin C (or DMSO) was added (100 nM) in
wells. Differentiation was analyzed after 8 d, and viability was assessed by
propidium iodide staining.
Active caspase-3 assay. SCIET27, SCIET27 transfected with PKC  
CAT, or SCIET27 transfected with A1 were irradiated (480 rads). At vari-
ous time points after irradiation, 106 cells were harvested, washed, and
fixed/ permeabilized. Active caspase-3 was detected using a PE-conjugated
active caspase-3 mAb (BD Biosciences).
Western blot analysis. Rag-2 /  sorted CD25  or CD25 44  (after anti-
CD3 injections) cells were used. As controls for the caspase-3 activation, we
have used embryonic fibroblasts from either WT or caspase-3    mice. Total
protein lysates were prepared as described by Aifantis et al. (7). The protein
blots were probed with anti-cleaved caspase-3 (Cell Signaling) and anti-actin
(Santa Cruz Biotechnology, Inc.) as an internal loading control.
Cytosolic Ca2  measurements. For Ca2  measurements, we have used
2   106 SCIET and SCB29 cells loaded with 1  M Fura2-AM (Molecular
Probes) dissolved in IMDM containing 1% FBS for 30 min at 37 C in the
dark. The exact protocol followed is described elsewhere (7).
Nuclear extracts and electrophoretic mobility shift assay. 5–10   106
SCIET cells were used for the preparation of nuclear protein extracts. The
details of the exact protocol used can be found elsewhere (7).
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